Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

摘要: Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study durvalumab versus placebo after CRT in patients with unresectable, stage non-small-cell lung cancer. If available, pre-CRT tissue tested for tumor-cell expression, scored at prespecified (25%) post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to intent-to-treat (ITT) population, most remained stable over time across subgroups, few clinically relevant differences between treatment arms. Time deterioration generally similar ITT population. Conclusion: Neither nor CRT-related influenced therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov).